What is this medicine used for?
FDA-approved uses
- Specified neuropathic pain and fibromyalgia — Adults. Includes diabetic peripheral neuropathy, postherpetic neuralgia, spinal-cord-injury neuropathic pain, and fibromyalgia.Lyrica immediate-release capsules; Lyrica oral solution.
- Adjunctive partial-onset seizure treatment — Adults and pediatric patients aged 1 month or older. Age- and weight-specific pediatric dosing; not a pediatric anxiety or pain approval.Lyrica immediate-release capsules; Lyrica oral solution.
Other uses (off-label)
Off-label means a medicine is prescribed for a use, age group or form that is not included in its FDA approval.
- Generalized anxiety disorder — Adults. US off-label use; European adult approval and NICE support in SSRI/SNRI intolerance do not establish FDA approval.Lyrica immediate-release capsules; Lyrica oral solution.
Read more: Generalized Anxiety Disorder.
What should I expect?
Some symptoms may improve before the full response is clear; full benefit can take several weeks or longer. Sleepiness, dizziness or swelling can appear early.
Review function as well as symptoms. Generalized-anxiety use is off-label in the United States, and should have an explicit plan for judging benefit and tolerability.
How do I take it safely?
The covered immediate-release capsules and liquid can be taken with or without food. Measure liquid with an oral dosing device. Lyrica CR has different instructions and is not a direct substitute.
Kidney function affects dosing. Avoid alcohol; review opioids, sedatives and medicines that increase swelling or facial-swelling risk. Do not drive until you know the effect on alertness and vision. Monitor weight, swelling, mood, vision and symptom benefit.
Discuss pregnancy and breastfeeding; the label advises against breastfeeding. Its pediatric seizure approval does not establish a pediatric anxiety indication. Keep this controlled medicine secure and never share it.
Do not stop abruptly. The label calls for tapering over at least one week, but a longer individualized plan may be needed. For a missed immediate-release dose, take it when remembered unless the next is near, then skip it; never double.
Existing respiratory disease, falls or unexplained muscle symptoms need review.
Do not use this product after a known allergy to its active medicine or ingredients; tell the pharmacist about previous medication reactions.
What side effects should I know about?
- Dizziness, sleepiness, blurred vision, edema, weight gain, dry mouth, and concentration difficulty.
Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.
Looking for more detailed information?
The official medicine information lists more side effects, safety advice and product instructions.
- View FDA Prescribing Information (PDF) (opens in a new tab)LYRICA- pregabalin capsule
Which warning signs need help?
- Swelling of the face, mouth, tongue or throat, or breathing difficulty, requires emergency care. The label directs stopping for serious allergic swelling; do not wait for a routine appointment.
- Profound sleepiness, slow breathing, inability to wake, collapse or a seizure emergency needs immediate help, particularly with opioids, sedatives or lung disease.
- Contact the prescriber promptly for new suicidal thoughts, worsening depression or unusual behavior. Use emergency care if there is immediate danger or the person cannot stay safe. Report new visual changes, marked swelling or unexplained muscle pain or weakness promptly. Rapid stopping can cause withdrawal and increased seizures. Suicidal thoughts or behavior have also been reported after stopping; continue watching for mood or behavior changes during and after a prescriber-guided reduction.
What else should I know to stay safe?
- Kidney function affects dosing. Review lung disease, falls, opioids, other sedatives and medicines that add swelling or allergic-swelling risk. Avoid alcohol; do not use after product allergy.
- Monitor weight, swelling, mood, vision, muscle symptoms and benefit. Discuss pregnancy; the label advises against breastfeeding. Pediatric seizure approval does not establish pediatric anxiety treatment.
- Keep this controlled medicine secure. Do not stop abruptly: the label specifies a taper of at least one week, but a longer individualized plan may be needed. Immediate- and extended-release products have different instructions.
Urgent help and crisis support · Emergency & Crisis Resources (US)
What can help day to day?
- Physical dependence and withdrawal can occur during prescribed treatment. Needing a gradual reduction is not, by itself, evidence of addiction.
- Weight gain or swollen ankles may affect everyday comfort and health. Bring them up at follow-up rather than waiting until they become severe.
How does it work?
Pregabalin attaches to part of certain calcium channels in nerve cells and can change the release of chemical messages involved in pain and other signaling. The full explanation for its clinical effects is uncertain. Although related in structure to GABA, it does not directly act at GABA’s receiving sites.
How was this medicine developed?
Lyrica capsules received FDA approval in 2004. Its US uses expanded across particular pain conditions, fibromyalgia and adjunctive seizure treatment. A generalized-anxiety approval in Europe does not create that approval in the United States.
How do I say the name?
Pregabalin: pre-GAB-a-lin. Capital letters show the stressed syllable.
Medicine forms and official information
Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.
Choose a formulation
Lyrica immediate-release capsules
25, 50, 75, 100, 150, 200, 225, and 300 mg capsules; taken by mouth.
Lyrica oral solution
20 mg/mL oral solution; taken by mouth.
Lyrica CR extended-release tablets
Separate once-daily after-evening-meal product; diabetic neuropathic pain and postherpetic neuralgia indications. No conversion provided.
Sources and References
Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.
- NICE generalized anxiety guideline: recommendation 1.2.25
- Lyrica: European product information, current October 2026 record
- Lyrica capsules and oral solution: current prescribing information
- Lyrica capsules: FDA approval history
- Lyrica CR extended-release tablets: distinct product scope
- Pregabalin: MedlinePlus Drug Information
- Lyrica: FDA prescribing information, April 2025
- Lyrica: Package Insert / Prescribing Information / MOA
- Gabapentinoids: FDA warning about serious breathing problems
- VA clinician guide: insufficient evidence for pregabalin in PTSD
- Neurontin: current prescribing information
- Pregabalin: verified neutral parent, PubChem CID 5486971
- ISMP List of Confused Drug Names
- High-Alert Medications in Long-Term Care (LTC) Settings
- ISMP List of High-Alert Medications in Community/Ambulatory Care Settings
Giving medicine safely to children: family guide (PDF, 3 pages)

